MedPath

EZETIMIBE

These highlights do not include all the information needed to use EZETIMIBE TABLETS safely and effectively. See full prescribing information for EZETIMIBE TABLETS. EZETIMIBE tablets, for oral use. Initial U.S. Approval: 2002

Approved
Approval ID

c07fe2e0-dad4-48b5-8a07-7d57a4035ccd

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 8, 2022

Manufacturers
FDA

Camber Pharmaceuticals, Inc.

DUNS: 826774775

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

EZETIMIBE

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code31722-628
Application NumberANDA210859
Product Classification
M
Marketing Category
C73584
G
Generic Name
EZETIMIBE
Product Specifications
Route of AdministrationORAL
Effective DateFebruary 8, 2022
FDA Product Classification

INGREDIENTS (8)

CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48
Classification: IACT
HYPROMELLOSE, UNSPECIFIEDInactive
Code: 3NXW29V3WO
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
SODIUM LAURYL SULFATEInactive
Code: 368GB5141J
Classification: IACT
EZETIMIBEActive
Quantity: 10 mg in 1 1
Code: EOR26LQQ24
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.